New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

BeaconMedIC has 73 videos Subscribe Here

Description: Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research.
Shared By : BeaconMedIC
Posted on : 08/28/18
Added : 12 months ago
Category : Prostate Cancer